# TAPISTRY (NCT04589845)

> Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

No report yet. It can be ordered.

- Drugs tested: entrectinib; alectinib; atezolizumab
- Indication: solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04589845
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Solid Tumors
- Interventions: Entrectinib; Entrectinib; Alectinib; Atezolizumab; Ipatasertib; Trastuzumab emtansine; Inavolisib; Belvarafenib; Pralsetinib; Divarasib; Camonsertib
- Enrollment: 920
- Primary outcome: All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

## Indexed commentary on TAPISTRY so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 11 posts on X
- 1 YouTube video
- 1 podcast episode

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tapistry-nct04589845

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04589845", "email": "<work email>"}; the inbox owner confirms by the emailed link.
